LCM
NPCE icon

Legato Capital Management’s Neuropace NPCE Stock Holding History

Legato Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
70,334
+2,133
+3% +$34.3K 0.09% 315
2026
Q1 		$897K Sell
68,201
-964
-1% -$14.5K 0.08% 320
2025
Q4 		$1.07M Buy
69,165
+6,120
+10% +$81.8K 0.09% 340
2025
Q3 		$650K Buy
63,045
+41,323
+190% +$390K 0.07% 404
2025
Q2 		$242K Sell
21,722
-19,385
-47% -$242K 0.03% 508
2025
Q1 		$505K Buy
+41,107
New +$515K 0.07% 422

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Legato Capital Management's NPCE Position: Q2 2026 in Review

Legato Capital Management increased its Neuropace (NPCE) stake by 3.1% in Q2 2026, buying an estimated $34.3K and bringing the position to 70,334 shares worth $1.12M. The position accounts for 0.09% of the portfolio, ranked #315.

Legato Capital Management first reported a position in NPCE in Q1 2025 and has held it in 6 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Legato Capital Management held 70,334 shares of Neuropace worth $1.12M as of Q2 2026.
  • Legato Capital Management bought 2,133 Neuropace shares in Q2 2026, an estimated $34.3K.
  • Neuropace made up 0.09% of Legato Capital Management's portfolio in Q2 2026, its #315 holding.
  • Legato Capital Management first reported a position in Neuropace in Q1 2025 and has held it in 6 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.